MarketCap
Facebook
X
TelegramIntersect ENT, Inc. Revenue 2011-2026 | XENT
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Intersect ENT, Inc.
| 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|
| 80.6 M | 109 M | 108 M | 96.3 M | 78.7 M | 61.6 M | 38.6 M | 17.9 M | 5.86 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 109 M | 5.86 M | 66.4 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Medical devices industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AdaptHealth Corp.
AHCO
|
3.24 B | $ 13.17 | 0.46 % | $ 1.78 B |  USA |
 |
BIOLASE
BIOL
|
49.2 M | - | -13.19 % | $ 166 K | USA |
 |
GenMark Diagnostics, Inc.
GNMK
|
172 M | - | - | $ 1.77 B | USA |
 |
Allied Healthcare Products
AHPI
|
6.02 M | - | 3.58 % | $ 2.21 M | USA |
 |
Eargo
EAR
|
37.2 M | - | - | $ 10.2 M | USA |
 |
Delcath Systems
DCTH
|
85.2 M | $ 10.8 | 4.05 % | $ 387 M | USA |
 |
Apollo Endosurgery
APEN
|
76.9 M | - | - | $ 475 M | USA |
 |
Obalon Therapeutics, Inc.
OBLN
|
1.59 M | - | -5.86 % | $ 30.6 M | USA |
 |
Second Sight Medical Products
EYES
|
1 K | - | -0.97 % | $ 54.4 M | USA |
 |
Electromed
ELMD
|
64 M | $ 25.6 | -0.43 % | $ 216 M | USA |
 |
Avinger
AVGR
|
7.65 M | - | -20.74 % | $ 369 K | USA |
 |
Axonics Modulation Technologies
AXNX
|
274 M | - | - | $ 3.31 B | USA |
 |
EDAP TMS S.A.
EDAP
|
44.1 M | $ 3.47 | 4.52 % | $ 130 M |  France |
 |
Aziyo Biologics
AZYO
|
12.3 M | - | 1.37 % | $ 20.5 M | USA |
 |
BioSig Technologies
BSGM
|
40 K | - | 37.08 % | $ 85.7 M | USA |
 |
Helius Medical Technologies
HSDT
|
644 K | $ 2.12 | 3.92 % | $ 1.29 M | USA |
 |
Inspire Medical Systems
INSP
|
912 M | $ 56.7 | 1.0 % | $ 1.67 B | USA |
 |
Conformis
CFMS
|
62 M | - | - | $ 16.4 M | USA |
 |
LivaNova PLC
LIVN
|
1.39 B | $ 61.0 | 1.5 % | $ 3.33 B |  Britain |
 |
ClearPoint Neuro
CLPT
|
37 M | $ 11.37 | 1.7 % | $ 322 M | USA |
 |
Cardiovascular Systems
CSII
|
236 M | - | 0.15 % | $ 844 M | USA |
 |
Cytosorbents Corporation
CTSO
|
37.1 M | $ 0.61 | 0.36 % | $ 38 M | USA |
 |
CryoLife, Inc.
CRY
|
253 M | - | -4.14 % | $ 702 M | USA |
 |
Invacare Corporation
IVC
|
181 M | - | - | $ 24.7 M | USA |
 |
Hancock Jaffe Laboratories, Inc.
HJLI
|
4.25 K | - | -1.98 % | $ 98.3 M | USA |
 |
IRIDEX Corporation
IRIX
|
52.7 M | $ 1.03 | - | $ 17.4 M | USA |
 |
Itamar Medical Ltd.
ITMR
|
41 M | - | 0.03 % | $ 1.58 B |  Israel |
 |
Dynatronics Corporation
DYNT
|
27.4 M | - | 14.99 % | $ 929 K | USA |
 |
Misonix, Inc.
MSON
|
62.5 M | - | - | $ 462 M | USA |
 |
Neovasc
NVCN
|
2.55 M | - | - | $ 111 M |  Canada |
 |
OrthoPediatrics Corp.
KIDS
|
236 M | $ 15.65 | 3.92 % | $ 367 M | USA |
 |
Butterfly Network
BFLY
|
82.1 M | $ 5.4 | 12.97 % | $ 1.14 B | USA |
 |
GBS
GBS
|
3.05 M | - | -0.57 % | $ 7.12 M | USA |
 |
Sintx Technologies
SINT
|
1.02 M | $ 2.41 | 14.22 % | $ 6.68 M | USA |
 |
Globus Medical
GMED
|
2.94 B | $ 91.34 | 1.29 % | $ 12.4 B | USA |
 |
TransMedics Group
TMDX
|
605 M | $ 100.01 | -0.77 % | $ 3.4 B | USA |
 |
NanoVibronix
NAOV
|
2.55 M | - | - | $ 1.08 M | USA |
 |
CONMED Corporation
CNMD
|
1.37 B | $ 36.8 | 0.38 % | $ 1.14 B | USA |
 |
Integer Holdings Corporation
ITGR
|
1.85 B | $ 84.03 | -5.06 % | $ 2.92 B | USA |
 |
Stryker Corporation
SYK
|
7.17 B | $ 294.73 | -6.47 % | $ 113 B | USA |
 |
Edwards Lifesciences Corporation
EW
|
6.07 B | $ 83.98 | 0.57 % | $ 49.1 B | USA |
 |
Tandem Diabetes Care
TNDM
|
290 M | $ 19.41 | -0.61 % | $ 1.32 B | USA |
 |
LENSAR
LNSR
|
58.4 M | $ 5.61 | 7.27 % | $ 67.1 M | USA |
 |
Pulmonx Corporation
LUNG
|
90.5 M | $ 1.35 | 5.47 % | $ 54.9 M | USA |
 |
MiMedx Group
MDXG
|
419 M | $ 3.68 | 9.52 % | $ 544 M | USA |
 |
Myomo
MYO
|
40.9 M | $ 0.9 | 4.16 % | $ 37.7 M | USA |